Literature DB >> 16596780

Effects of cannabinoids on neurotransmission.

B Szabo1, E Schlicker.   

Abstract

The CB1 cannabinoid receptor is widely distributed in the central and peripheral nervous system. Within the neuron, the CB1 receptor is often localised in axon terminals, and its activation leads to inhibition of transmitter release. The consequence is inhibition of neurotransmission via a presynaptic mechanism. Inhibition of glutamatergic, GABAergic, glycinergic, cholinergic, noradrenergic and serotonergic neurotransmission has been observed in many regions of the central nervous system. In the peripheral nervous system, CB1 receptor-mediated inhibition of adrenergic, cholinergic and sensory neuroeffector transmission has been frequently observed. It is characteristic for the ubiquitous operation of CB1 receptor-mediated presynaptic inhibition that antagonistic components of functional systems (for example, the excitatory and inhibitory inputs of the same neuron) are simultaneously inhibited by cannabinoids. Inhibition of voltage-dependent calcium channels, activation of potassium channels and direct interference with the synaptic vesicle release mechanism are all implicated in the cannabinoid-evoked inhibition of transmitter release. Many presynaptic CB1 receptors are subject to an endogenous tone, i.e. they are constitutively active and/or are continuously activated by endocannabinoids. Compared with the abundant data on presynaptic inhibition by cannabinoids, there are only a few examples for cannabinoid action on the somadendritic parts of neurons in situ.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16596780     DOI: 10.1007/3-540-26573-2_11

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  69 in total

1.  Are CB(1) Receptor Antagonists Nootropic or Cognitive Impairing Agents?

Authors:  Stephen A Varvel; Laura E Wise; Aron H Lichtman
Journal:  Drug Dev Res       Date:  2009-12-01       Impact factor: 4.360

2.  Purine receptor-mediated endocannabinoid production and retrograde synaptic signalling in the cerebellar cortex.

Authors:  Flora E Kovacs; Peter Illes; Bela Szabo
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 3.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

4.  Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol.

Authors:  Joshua A Lile; Michael J Wesley; Thomas H Kelly; Lon R Hays
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

Review 5.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

6.  Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol.

Authors:  Bela Szabo; Michal J Urbanski; Tiziana Bisogno; Vincenzo Di Marzo; Aitziber Mendiguren; Wolfram U Baer; Ilka Freiman
Journal:  J Physiol       Date:  2006-09-14       Impact factor: 5.182

Review 7.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 8.  Cyclooxygenase-2 in synaptic signaling.

Authors:  Hongwei Yang; Chu Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

9.  Pre-encoding administration of amphetamine or THC preferentially modulates emotional memory in humans.

Authors:  Michael E Ballard; David A Gallo; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2012-12-09       Impact factor: 4.530

Review 10.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.